N-acetyltransferase (NAT2) genotype and susceptibility to sporadic Alzheimer's disease

Pharmacogenetics

Volumn 9, Issue 1, 1999, Pages 9-15

  Rocha, Luísa ^a   Garcia, Carlos ^b   De Mendonça, Alexandre ^b   Gil, José Pedro ^a   Bishop, D Timothy ^c   Lechner, Maria Celeste ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b Faculty of Medicin   (Portugal)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Genotype; NAT2 alleles; Polymorphism

Indexed keywords

ACYLTRANSFERASE;

ACETYLATOR PHENOTYPE; ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENOTOXICITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0032950492     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199902000-00002     Document Type: Article

References (31)

1. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drug and carcinogens in humans. Proc Natl Acad Sci U S A 1991; 88:5237-5241.
2. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine. N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57:581-592.
3. Corey-Bloom J, Thal LJ, Galasko D, Folstein M, Druchmad D, Raskind M, Lanska DJ. Diagnosis and evaluation of dementia. Neurol 1995; 45:211-218.
4. Cotman CW, Su JH. Mechanisms of neuronal cell death in Alzheimer's Disease. Brain Pathol 1996; 6:493-506.
5. Dupret J-M, Goodfellow GH, Janezie SA, Grant DM. Structure-function studies of human Arylamine N-Acetyltransferases NAT1 and NAT2. J Biol Chem 1994; 269:26830-26835.
6. Evans DA. N-Acetyltransferase. In: Pharmacogenetics of drug metabolism. Kalow W (editor). New York: Pergamon; 1992. pp. 95-178.
7. Gil JP, Lechner MC. Increased Frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese colon cancer patients. Carcinogenesis 1998; 19:37-41.
8. Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349:704-706.
9. Grant DM. Molecular genetics of the acetyltransferases. Xth International symposium on microsomes and drug oxidations. University of Toronto, Toronto, Canada; 1994. pp. 12-14.
10. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994; 3:729-734.
11. Innis MA, Gelfand DH, Sninsky JJ, While TJ. PCR Protocols. A guide to methods and applications. London: Academic Press; 1990.
12. Kamboh MI. Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. Hum Biol 1995; 67:195-215.
13. Ladero JM, Barquero MS, Coria F, Molina JA, Jimenez-Jimenez FJ, Benitez J. Acetylator polymorphism in Alzheimer's Disease. Eur J Med 1993; 2:281-283.
14. Levy-Lahad E, Bird TD. Genetic factors in Alzheimer's disease: a review of recent advances. Ann Neurol 1996; 40:829-840.
15. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima JM, Pettingell WH, et al. Candidate gene for the chromosome I familial Alzheimer's Disease locus. Science 1995; 269:973-977.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurol 1984; 34: 939-944.
17. Meyer UA. Drugs in special patient groups: clinical importance of genetics in drug effects. In: Clinical pharmacology: basic principles of therapeutics. McImon KF, Morelli HF (editors). New York: McGraw-Hill; 1992. p. 875.
18. Nebert DW, Weber WW. Pharmacogenetics, in principles of drug action. In: The basis of pharmacology. New York: Churchill Livingstone; 1990. p. 469-531.
19. Nebert DW. Proposed role of drug-metabolizing enzymes: regulation of steady slate levels of the ligands that effect growth, homeostasis, differentiation and neuroendocrine functions. Mol Endocr 1991; 5:1203-1214.
20. Nee LE, Eldridge R, Sunderland T, Thomas CB, Katz D, Thompson KE, et al. Dementia of the Alzheimer type: clinical and family study of 22 twin pairs. Neurol 1987; 37:359-363.
21. Pacifici GM, Fracchia GN. Medicine and health. Advances in drug metabolism in man. EUR 15439. Luxemburg: Office for Official Publications of the European Communities; 1995.
22. Price DL, Cork LC, Struble RG, Kitt CA, Walker LC, Powers RE, et al. Dysfunction and death of neurons in human degenerative neurological diseases and in animal models. Ciba Foundation Symposium 1987; 126:30-48.
23. Rocha L, de Mendonça A, Garcia C, Lechner MC. Apolipoprotein E genotype of a Portuguese control population and Alzheimer's disease patients. Eur J Neurol 1997; 5:448-452.
24. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47:387-400.
25. Sasieni PD. From genotypes to genes: doubling the sample size. Biometrics 1997; 53:1253-1261.
26. Saunders AM, Strittmatter WJ, Schemechel D, St George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurol 1993; 43:1467-1472.
27. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning a novel gene bearing missence mutations in early onset familial Alzheimer's Disease. Nature 1995; 375:754-760.
28. Spurr NK, Gough AC, Chinegwundoh FI, Dale Smith CA. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin Chem 1995; 41:1864-1867.
29. Tanzi RE, Kovacs DM, Kim T-W, Moir RD, Guenette SY, Wasco W. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 1996; 3:159-168.
30. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267:1456-1462.
31. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Evans DAP, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5:1-17.